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Background
Nitric oxide signaling through the cGMP kinase
(cGK1a) activates Myosin Phosphatase (MP) leading to
calcium de-sensitization of force production. Leucine
zipper (LZ) motifs present in the C-terminus of MYPT1
and N-terminus of cGK1a are thought to be essential
f o rt h eh e t e r o - d i m e r i z a t i o no fc G K 1a n dM Y P T 1a n d
cGK1 activation of MP [1]. An isoform of MYPT1 that
lacks the C-terminal LZ motif is generated by the alter-
native splicing of a 31 nt 3’ exon (E23). We have shown
that the expression of these MYPT1 isoforms is tissue-
specific, developmentally regulated and modulates in
disease [2]. MYPT1 E23-/LZ+ isoform is expressed in
tonic smooth muscle of the large arteries and veins
while MYPT1 E23+/LZ- isoform is expressed in the
phasic smooth muscle of the intestines, portal vein and
small resistance arteries. There is a good though incom-
pletely characterized correlation between the expression
of MYPT1 isoforms and sensitivity to NO/cGMP-
mediated relaxation, making this alternative splicing
event an excellent model for the study of smooth mus-
cle phenotypic diversity in relation to vascular function.
Results
In a previous study we identified Transformer (Tra2b), a
master regulator of splicing and sex determination in
Drosophila, as a candidate tissue-specific regulator of
MYPT1 E23 splicing [3]. We now examine this question
in the mouse in order to take advantage of a conditional
Sfrs10 (Tra2b) knockout model [1]. As in the rat 1)
Tra2b is expressed at higher levels in phasic smooth
muscle of small arteries and intestines, where E23 is
spliced as compared to tonic smooth muscle of large
vessels, where E23 is skipped. 2) Tra2b is developmen-
tally up-regulated as smooth muscle acquires a phasic
phenotype/E23 splicing. To test the role of Tra2b in
vivo, SM22Cre and Tra2b flox mice were crossed for
conditional inactivation of Tra2b in smooth muscle. The
homozygous (Cre+//f/f) mice are non-viable. Heterozy-
gous mice (Cre+//f/+) have significantly decreased levels
of MYPT1 E23 inclusion in many of the phasic smooth
muscle tissues.
Conclusion
Tra2b is necessary for tissue-specific splicing of MYPT1
E23. Tra2b may function as a master regulator of
smooth muscle phenotype and responses to NO/cGMP
signaling.
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